03.17.23
Herbal extract manufacturer and supplier HP Ingredients has launched a new proprietary blend called NuFemme, which combines Labisia pumila and Eurycoma longifolia (LJ100) standardized extracts.
NuFemme is supported by a randomized, double-blind, placebo-controlled human clinical trial published in Food & Nutrition Research in 2020. In this study, 119 women aged 41 to 55, who were experiencing peri-menopausal or menopausal symptoms, consumed either 55 mg NuFemme or placebo daily for 24 weeks.
The primary objective was to discern changes in symptoms, notably hot flashes, and the secondary objective was to assess potentially significant changes in Menopause Rating Scale (MRS) and Menopause Specific Quality of Life Questionnaire (MENQOL) domain scores as well as in concentrations of serum hormone and lipid profile, bone markers, sleep quality, and vitality.
Researchers noted there were significant improvements in MRS and MENQOL scores at weeks 12 and 14, respectively. And while not statistically significant, hot flashes improved 5% more in the NuFemme group compared to the placebo group at week 12.
Additionally at weeks 12 and 24, there were significant reductions in serum low-density lipid and triglycerides levels in the NuFemme group, with no changes in placebo group. Also, luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels were significantly reduced at week 12 and 24 compared to baseline in the NuFemme group, with no significant changes observed in the placebo group.
The researchers concluded that NuFemme supplementation “may support reduction in hot flushes, improvements in hormone and lipid profile in healthy peri-menopausal and menopausal women.”
“NuFemme is an ingredient that is versatile for formulators,” said Annie Eng, CEO and founder of HP Ingredients, a certified Woman-Owned business. “It can be a standalone ingredient in a women-focused line of products, it can be blended with other proven menopausal-support ingredients for a targeted formula, and it can also be incorporated into multivitamins targeted towards women experiencing peri-menopausal symptoms.”
NuFemme is supported by a randomized, double-blind, placebo-controlled human clinical trial published in Food & Nutrition Research in 2020. In this study, 119 women aged 41 to 55, who were experiencing peri-menopausal or menopausal symptoms, consumed either 55 mg NuFemme or placebo daily for 24 weeks.
The primary objective was to discern changes in symptoms, notably hot flashes, and the secondary objective was to assess potentially significant changes in Menopause Rating Scale (MRS) and Menopause Specific Quality of Life Questionnaire (MENQOL) domain scores as well as in concentrations of serum hormone and lipid profile, bone markers, sleep quality, and vitality.
Researchers noted there were significant improvements in MRS and MENQOL scores at weeks 12 and 14, respectively. And while not statistically significant, hot flashes improved 5% more in the NuFemme group compared to the placebo group at week 12.
Additionally at weeks 12 and 24, there were significant reductions in serum low-density lipid and triglycerides levels in the NuFemme group, with no changes in placebo group. Also, luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels were significantly reduced at week 12 and 24 compared to baseline in the NuFemme group, with no significant changes observed in the placebo group.
The researchers concluded that NuFemme supplementation “may support reduction in hot flushes, improvements in hormone and lipid profile in healthy peri-menopausal and menopausal women.”
“NuFemme is an ingredient that is versatile for formulators,” said Annie Eng, CEO and founder of HP Ingredients, a certified Woman-Owned business. “It can be a standalone ingredient in a women-focused line of products, it can be blended with other proven menopausal-support ingredients for a targeted formula, and it can also be incorporated into multivitamins targeted towards women experiencing peri-menopausal symptoms.”
